CervoMed filed a Form 8-K reporting fourth-quarter and full-year 2025 results and corporate updates. Cash, cash equivalents and marketable securities were USD 20.9 million at Dec. 31, 2025, and the company said this is expected to fund operating expenses and capital expenditure for about six months. Full-year grant revenue fell 59% to USD 4 million, reflecting the completion of the randomized phase of the RewinD-LB trial in late 2024 and the extension phase in mid-2025. Full-year R&D expenses rose 16% to USD 21.8 million, driven by higher personnel and consulting costs, CMC work tied to RewinD-LB batch issues and pre-Phase 3 manufacturing improvements, and expenses for the RAS and nfvPPA trials initiated in 2025. Full-year net loss widened to USD 27 million and G&A expenses increased to USD 10.5 million, while CEO John Alam said CervoMed plans to initiate a single global Phase 3 DLB trial in the second half of 2026 subject to funding and expects multiple catalysts in the second half of 2026, including Phase 2a ischemic stroke recovery topline data and initial Phase 2a nfvPPA topline data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008611), on March 17, 2026, and is solely responsible for the information contained therein.
Comments